Inhibition of TGFβ signaling and its implications in anticancer treatments

Experimental Oncology

Volumn 34, Issue 1, 2012, Pages 9-16

  Calone, I ^a   Souchelnytskyi, S ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer; Inhibition of TGF signaling; TGF ; Therapeutic strategy

Indexed keywords

1D11; 2 (5 CHLORO 2 FLUOROPHENYL) 4 (4 PYRIDINYLAMINO)PTERIDINE; 2G7; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; A 83 01; ANTINEOPLASTIC AGENT; ANTP SM2A; AP 11014; AP 15012; BELAGENPUMATUCEL L; BEVACIZUMAB; DISITERTIDE; FRESOLIMUMAB; GW6604; IN 1130; KI26894; LERDELIMUMAB; LY2109761; LY2157299; LY364947; LY550410; LY580276; METELIMUMAB; NPC 30345; P17; RANAGENGLIOTUCEL T; SB 505124; SD 093; SIS3; SM305; SML6; SR 2F; SRIII; SX 007; TASISULAM; TRABEDERSEN; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; TRX CBP; TRX FOXHLB; TRX LEFL; TRX SARA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG RECEPTOR BINDING; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84862488155     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Holley RW. A unifying hypothesis concerning the nature of malignant growth. Proc Natl Acad Sci USA 1972; 69: 2840-1.
2. Moses HL, Roberts AB. The discovery of TGF-β: a historical perspective. In: The TGF-β Family. Derynck R, Miyazono K, eds. New York: Cold Spring Harbor Laboratory Press, 2008: 1-28.
3. Roberts AB, Anzano MA, Wakefield LM, et al. Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci USA 1985; 82: 119-23. (Pubitemid 15168226)
4. Witz IP. Yin-Yang activities and vicious cycles in the tumor microenvironment. Cancer Res 2008; 68: 9-13. (Pubitemid 351380098)
5. Massagué J. TGFβ in cancer. Cell 2008; 134: 215-30.
6. Tan AR, Alexe G, Reiss M. Transforming growth factor-β signaling emerging stem cell target in metastatic breast cancer. Breast Cancer Res Treat 2009; 115: 1-63.
7. Dumont N, Arteaga CL. Transforming growth factor-β and breast cancer: tumor promoting effects of transforming growth factor-β. Breast Cancer Res 2000; 2: 125-32. (Pubitemid 32223575)
8. Ikushima H, Miyazono K. TGFβ signalling: a complex web in cancer progression. Nat Rev Cancer 2010; 10: 415-24.
9. Roberts AB, Wakefield LM. The two faces of transforming growth factor in carcinogenesis. Proc Natl Acad Sci USA 2003; 100: 8621-3. (Pubitemid 36899145)
10. Muraoka-Cook RS, Dumont N, Arteaga CL. Dual role of transforming growth factor B in mammary tumorigenesis and metastatic progression. Clin Cancer Res 2005; 11: 937-43.
11. Kowanetz M. Novel regulators of the TGF-β signaling pathway. Acta Universitatis Upsaliensis. Digital comprehensive summaries of Uppsala dissertations from the Faculty of Medicine 57. 2005; 69pp. ISBN 91-554-6303-7.
12. Shi Y, Massagué J. Mechanism of TGF-β signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700. (Pubitemid 36724933)
13. Wrana JL, Attisano L, Wieser R, et al. Mechanism of activation of the TGF-β receptor. Nature 1994; 370: 341-7.
14. Attisano L, Wrana JL. Signal transduction by the TGF-β superfamily. Science 2002; 296: 1646-7.
15. Massagué J. TGF-β signal transduction. Annu Rev Biochem 1998; 67: 753-91.
16. Moustakas A, Heldin CH. The regulation of TGFßsignal transduction. Development 2009; 136: 3699-714.
17. Feng XH, Derynck R. Specificity and versatility in TGF-β signaling through Smads. Annu Rev Cell Dev Biol 2005; 21: 659-93. (Pubitemid 41740650)
18. Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol 2005; 23: 2078-93. (Pubitemid 46211385)
19. Matsuzaki K. Smad phosphoisoform signaling specificity: the right place at the right time. Carcinogenesis 2011; 32: 1578-88.
20. Ikushima H, Miyazono K. TGF-β signal transduction spreading to a wider field: a broad variety of mechanisms for context-dependent effects of TGF-β. Cell Tissue Res 2012; 347: 37-49.
21. Kang JS, Liu C, Derynck R. New regulatory mechanisms of TGF-β receptor function. Trends Cell Biol 2009; 19: 385-94.
22. Nakao A, Imamura T, Souchelnytskyi S, et al. TGF-β receptor-mediated signalling trough Smad2, Smad3 and Smad4. EMBO J 1997; 16: 5353-62. (Pubitemid 27380143)
23. Dennler S, Itoh S, Vivien D, et al. Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998; 17: 3091-100. (Pubitemid 28254381)
24. Derynck R, Zhang YE. Smad-dependent and Smadindependent pathways in TGF-b family signalling. Nature 2003; 425: 577-84. (Pubitemid 37280136)
25. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res 2009; 19: 128-39.
26. Parvani JG, Taylor MA, Schiemann WP. Noncanonical TGF-β signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia 2011; 16: 127-46.
27. Mu Y, Gudey SK, Landström M. Non-Smad signaling pathways. Cell Tissue Res 2012; 347: 11-20.
28. Moustakas A, Heldin CH. Non-Smad TGF-β signals. J Cell Sci 2005; 118: 3573-84.
29. Nagaraj NS, Datta PK. Targeting the transforming growth factor-β signaling pathway in human cancer. Expert Opin Investig Drugs 2010; 19: 77-91.
30. Harel-Bellan A. Silence, clean up genes! Med Sci (Paris) 2006; 22: 993-4. (Pubitemid 44845313)
31. Ait-Si-Ali S, Guasconi V, Harel-Bellan A. RNA interference and its possible use in cancer therapy. Bull Cancer 2004; 91:15-8. (Pubitemid 38230456)
32. Chan, JHP, Lim S, Wong WSF. Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 2006; 33: 533-40.
33. Bogdahn U, Hau P, Brawanski A, et al. Specific therapy for high-grade glioma by convection enhanced delivery of the TGF-β2 specific antisense oligonucleotide AP12009. Proc Am Soc Clin Oncol 2004; 23: 110.
34. Bogdahn U, Hau P, Stockhammer G, et al. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 2011; 13: 132-42.
35. Antisense Pharma. 1st June 2011; Press release.
36. Lahn M, Kloeker S, Berry BS. TGF-β inhibitors for the treatment of cancer. Expert Opin Invest Drugs 2005; 14: 629-41.
37. Misra A, Ganesh S, Shahiwala A, et al. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci 2003; 6: 252-273. (Pubitemid 37207232)
38. Antisense Pharma. 7th June 2011; Press release.
39. PR Newswire. 4th November 2009; Press release.
40. Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of Belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006; 24: 4721-30. (Pubitemid 46630936)
41. Nemunaitis J, Nemunaitis M, Senzer N, et al. Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non-small cell lung cancer (NSCLC) patients. Cancer Gene Ther 2009; 16: 620-4.
42. Waldmann TA. Immunotherapy: past, present and future. Nature Med 2003; 9: 269-77. (Pubitemid 36362781)
43. Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs 2009; 1: 539-47.
44. Stewart TJ, Smyth MJ. Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev 2011; 30: 125-40.
45. Morris JC, Shapiro GI, Tan AR, et al. Phase I/II study of GC1008: A human anti-transforming growth factor-beta (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J Clin Oncol 2008; 26: 9028.
46. Khaw P, Grehn F, Holló GP, et al. A phase III study of sub-conjunctival human anti-transforming growth factor beta (2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology 2007; 114: 1822-30.
47. Denton CP, Merkel PA, Furst DE, et al. Recombinant human anti-transforming growth factor 1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007; 56: 323-33. (Pubitemid 46106206)
48. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-β signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004; 3: 1011-22. (Pubitemid 39642364)
49. th February 2004; The Independent (London).
50. Christiansen J, Rajasekaran AK. Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol Cancer Ther 2004; 3: 1493-501. (Pubitemid 39562594)
51. Halder SK, Beauchamp RD, Datta PK. A specific inhibitor of TGF-β receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia 2005; 7: 509-21. (Pubitemid 40791869)
52. Laping NJ, Grygielko E, Mathur A, et al. Inhibition of transforming growth factor (TGF)-β1-induced extracellular matrix with a novel inhibitor of the TGF-β type I receptor kinase activity: SB-431542. Mol Pharmacol 2002; 62: 58-64. (Pubitemid 34680516)
53. DaCosta Byfield S, Major C, Laping NJ, et al. SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5 and ALK7. Mol Pharmacol 2004; 65: 744-52. (Pubitemid 38264042)
54. Fabian MA, Biggs WH 3rd, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinases inhibitors. Nat Biotechnol2005; 23: 329-36. (Pubitemid 41094421)
55. Noble MEM, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004; 303: 1800-5. (Pubitemid 38374863)
56. Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 2009; 48:964-70.
57. Yakymovych I, Engström U, Grimsby S, et al. Inhibition of transforming growth factor beta signaling by low molecular weight compounds interfering with ATP- or biding sites of the TGF beta type I receptor kinase. Biochemistry 2002; 41: 11000-7. (Pubitemid 35001214)
58. Schlingensiepen KH, Bischof A, Egger T, et al. The TGF-β1 antisense oligonucleotide AP 11014 for the treatment of non-small-cell lung, colorectal and prostate cancer: preclinical studies. Proc Am Soc Clin Oncol 2004; 23: 227.
59. Izumi K, Mizokami A, Li YQ, et al. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor β1-associated osteoblastic changes. The prostate 2009; 69: 1222-34.
60. Chakrabarti R, Subramaniam V, Abdalla S, et al. Tranilast inhibits the growth and metastasis of mammary carcinoma. Anticancer Drugs 2009; 20: 334-45.
61. Subramaniam V, Chakrabarti R, Prud'homme GJ, et al. Tranilast inhibits cell proliferation and migration and promotes apoptosis in murine breast cancer. Anticancer Drugs 2010; 21: 351-61.
62. Subramaniam V, Ace O, Prud'homme GJ, et al. Tranilast treatment decreases cell growth, migration and inhibits colony formation of human breast cancer cells. Exp Mol Pathol 2011; 90: 116-22.
63. Lee SH, Leem HS, Jeong SM, et al. Bevacizumab accelerates corneal wound healing by inhibiting TGF-β2 expression in alkali-burned mouse cornea. BMB Rep 2009; 42: 800-5.
64. Ge L, Hoa N, Bota D A, et al. Phase I clinical trial of a TGF-b antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther 2006; 13: 1052-60.
65. Ge L, Hoa N, Bota D A, et al. Immunotherapy of brain cancers: the past, the present, and future directions. Clin Dev Immunol 2010; 2010: 296453.
66. Grehn F, Holló GP, Khaw P, et al. Factors affecting the outcome of trabeculectomy: an analysis based on combined data from two phase III studies of an antibody to transforming growth factor beta2, CAT-152. F. Ophthalmology 2007; 114: 1831-8.
67. Yang YA, Dukhanina O, Tang B, et al. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse effects. J Clin Invest 2002; 109: 1607-15. (Pubitemid 34663523)
68. Ganapathy V, Ge R, Grazioli AV, et al. Targeting the transforming growth factor-β pathway inhibits human basallike breast cancer metastasis. Mol Cancer 2010; 9:122.
69. Arteaga CL, Hurd SD, Winnier AR, et al. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest 1993; 92: 2569-76. (Pubitemid 24006519)
70. Biswas S, Guix M, Rinehart C, et al. Inhibition of TGF-β with neutralizing antibodies prevents radiationinduced acceleration of metastatic cancer progression. J Clin Invest 2007; 117: 1305-13. (Pubitemid 46718418)
71. Tojo M, Hamashima Y, Hanyu A, et al. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-tomesenchymal transition by transforming growth factor-beta. Cancer Sci 2005; 96: 791-800. (Pubitemid 43019830)
72. de Gouville AC, Boullay V, Krysa G, et al. Inhibition of TGF-β signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br J Pharmacol 2005; 145: 166-77. (Pubitemid 40756521)
73. Laping NJ, Huet S. TGF-β receptor kinase inhibitors for the treatment of fibrosis. In: Smad signal transduction: Smads in proliferation, differentiation and disease. ten Dijke P and Heldin C-H eds. Springer Verlag, 2006: 443-59.
74. Moon JA, Kim HT, Cho IS, et al. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int 2006; 70: 1234-43.
75. Ehata S, Hanyu A, Fujime M, et al. Ki26894, a novel transforming growth factor-β type I receptor kinase inhibitor, inhibits in vitro bone metastasis of a human breast cancer cell line. Cancer Sci 2007; 98: 127-33. (Pubitemid 44803931)
76. Bueno L, de Alwis DP, Pitou C. Semi-mechanistic modeling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-b kinase antagonist, in mice. Eur J Cancer 2008; 44: 142-50. (Pubitemid 350256941)
77. Sawyer JS, Anderson BD, Beight DW, et al. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. J Med Chem 2003; 46: 3953-6. (Pubitemid 37122441)
78. Haritunians T, Gueller S, O'Kelly J, et al. Novel acyl sulfonamide LY573636-sodium: effect on hematopoietic malignant cells. Oncol Rep 2008; 20: 1237-42.
79. Roxanne Nelson. Lilly Suspends Study of Tasisulam for Metastatic Melanoma. Medscape Medical News Oncology.
80. Singh J, Chuaqui CE, Boriack-Sjodin PA, et al. Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGF-β receptor kinase (TßRI). Bioorg Med Chem Lett 2003; 13: 4355-9. (Pubitemid 37490817)
81. Ge R, Rajeev V, Subramanian G, et al. Selective inhibitors of type I receptor kinase block cellular transforming growth factor-β signaling. Biochem Pharmacol 2004; 68: 41-50. (Pubitemid 38746540)
82. Ge R, Rajeev V, Ray P, et al. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-β type I receptor kinase in vivo. Clin Cancer Res 2006; 12: 4315-30.
83. Uhl M, Aulwurm S, Wischhusen J, et al. SD-208 a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004; 64: 7954-61. (Pubitemid 39446929)
84. Suzuki E, Kim S, Cheung HK, et al. A novel smallmolecule inhibitor of transforming growth factor β type I kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 2007; 67: 2351-9. (Pubitemid 46424257)
85. Ishida W, Mori Y, Lakos G, et al. Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. J Invest Dermatol 2006; 126:1733-44. (Pubitemid 44086506)
86. Tran TT, Uhl M, Ma JY, et al. Inhibiting TGF-β signaling restores immune surveillance in the SMA-560 glioma model. Neuro Oncol 2007; 9: 259-70. Erratum in Neuro Oncol 2007; 9: 465. (Pubitemid 47169658)
87. Melisi D, Ishiyama S, Sclabas GM, et al. LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 2008; 7: 829-40. (Pubitemid 351551036)
88. Vicent S, Luis-Ravelo D, Antón I, et al. A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism. Cancer Res 2008; 68: 2275-85. (Pubitemid 351521801)
89. th March 2010; Press release.
90. Gil-Guerrero L, Dotor J, Huibregtse IL, et al. In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-beta1. J Immunol 2008; 81: 126-35.
91. Bandyopadhyay A, Zhu Y, Cibull ML, et al. A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDAMB-231 cells. Cancer Res 1999; 59: 5041-6. (Pubitemid 29472913)
92. Bandyopadhyay A, Zhu Y, Malik SN, et al. Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene 2002; 21: 3541-51. (Pubitemid 34587686)
93. Cui Q, Lim SK, Zhao B, et al. Selective inhibition of TGF-responsive genes by Smad-interacting peptide apta mers from FoxH1, Lef1 and CBP. Oncogene 2005; 24: 3864-74. (Pubitemid 40896398)
94. Zhao BM, M.F Hoffman MF. Inhibition of transforming growth factor-beta1-induced signaling and epithelial-tomesenchymal transition by the Smad-binding peptide aptamer Trx-SARA. Mol Biol Cell 2006; 17: 3819-31. (Pubitemid 44330868)
95. Jinnin M, Ihn H, Tamaki K. Characterization of SIS3, a novel specific inhibitor of smad3, and its effect on transforming growth factor-beta-1-induced extracellular matrix expression. Mol Pharmacol 2006; 69: 597-607. (Pubitemid 43121957)